ArticleInternational urology and nephrology2026
Clinical experience with sodium-glucose transport 2 (SGLT2) inhibitors in patients with systemic lupus erythematosus.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Methodological considerations regarding confounding and multivariable adjustment in evaluating SGLT2 inhibitors in systemic lupus erythematosus?International urology and nephrology · 2026Article
- Review
- Authors' reply: The role of real-world evidence in evaluating SGLT2 inhibitors in systemic lupus erythematosus.International urology and nephrology · 2026Article
- Comment on "Clinical experience with SGLT2 inhibitors in patients with systemic lupus erythematosus".International urology and nephrology · 2026Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesEffective management of chronic kidney disease (CKD) in systemic lupus erythematosus (SLE) is crucial for reducing long-term complications. Sodium-glucose transport 2 inhibitors (SGLT2is) improve renal and cardiovascular outcomes of non-SLE-related CKD. We aimed to assess clinical characteristics and outcomes of SLE patients treated with SGLT2is.
methodsThis retrospective study evaluated adult SLE patients treated with SGLT2is for ≥ 3 months compared to untreated patients. Disease-related characteristics, kidney-related factors, and comorbidities were assessed. Repeated measures analysis model was applied to compare estimated glomerular filtration rate (eGFR) at different timepoints. Additional outcomes included infections, hospitalizations, and all-cause mortality. In SGLT2is-treated patients, eGFR and albuminuria were recorded before SGLT2is initiation, at 1 month, and 1 year following SGLT2is initiation.
resultsA total of 112 consecutive patients were included with a mean follow-up of 18.1 ± 12.7 years since SLE diagnosis. The use of SGLT2is in 9 SLE patients showed a stable kidney function over-time (60 ml/min/m
conclusionsThis study suggests a potential benefit of SGLT2is in SLE patients. Further research is needed to confirm the nephro- and cardioprotective effects of SGLT2is in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.